Cargando…
Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?
We assessed the impact of new antineoplastic agents on the overall survival (OS) of advanced non-small cell lung cancer (aNSCLC) patients followed up until 2012. Multivariate regression models were run for OS (outcome) and four proxies for innovation (exposure): Index (InnovInd, for SEER-Research da...
Autores principales: | Justo, Nahila, Nilsson, Jonas, Korytowsky, Beata, Dalen, Johan, Madison, Terri, McGuire, Alistair |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217468/ https://www.ncbi.nlm.nih.gov/pubmed/32396541 http://dx.doi.org/10.1371/journal.pone.0232669 |
Ejemplares similares
-
COVID-19 and Pregnancy: Have We Gotten through the Darkest Hour?
por: Favilli, Alessandro, et al.
Publicado: (2022) -
PDGFRα inhibition in soft-tissue sarcomas: Have we gotten it all wrong?
por: Napolitano, Andrea, et al.
Publicado: (2019) -
Diabetes Has Gotten Pretty Darn Complicated
por: Skolnik, Neil, et al.
Publicado: (2015) -
Review of Two Decades of Cholera Diagnostics – How Far Have We Really Come?
por: Dick, Michal H., et al.
Publicado: (2012) -
Mitochondrial Neurogastrointestinal Encephalomyopathy: Into the Fourth Decade, What We Have Learned So Far
por: Pacitti, Dario, et al.
Publicado: (2018)